Moderna publishes transcript of Q2 2026 earnings call

• Moderna’s Q2 2026 earnings call featured CEO Stephane Bancel, President Stephen Hoge, CFO James Mock, CDO David Berman, investor relations lead Lavina Talukdar.
• Revenue totaled USD 145 million; net loss USD 782 million; cash and investments USD 6.9 billion; 2026 revenue outlook reiterated at up to 10% growth.
• Cost of sales outlook cut to USD 1.7 billion, including a USD 900 million litigation settlement charge; R&D outlook trimmed to USD 2.9 billion.
• Flu vaccine mRNA-1010 won a unanimous VRBPAC recommendation; FDA PDUFA date set for Aug. 5; reviews ongoing in EU, Canada, Australia.
• Intismeran Phase III adjuvant melanoma study fully enrolled; interim analysis expected in 2H 2026; management plans a press release on interim results.
• Norovirus vaccine mRNA-1403 missed interim early-success criteria; trial remains blinded; Moderna plans a fourth cohort as case accrual ran slower than expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.